Bayer AG Sponsored ADR (BAYRY)
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Bayer Aktiengesellschaft (BAYRY) and Roche Holding AG (RHHBY). But which of these two companies is the best option for those looking for undervalued stocks?
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
BAYRY wins FDA priority review for sevabertinib in first-line HER2-mutant NSCLC, building momentum for the oral TKI.
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
BAYRY gains FDA Priority Review for asundexian NDA after phase III data showed a 26% cut in ischemic stroke risk without more major bleeding.
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Aktiengesellschaft ETR: BAYN executives said the company's Crop Science division remains on track with a five-year plan centered on cost savings, margin expansion and a slate of product launches in seeds, traits and crop protection.
Bayer Net Profit Surges Driven by Growth in Agricultural Division
The group's net profit was aided by a gain from the sale of an antibiotics business and stronger underlying earnings at its agricultural division.
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.
Bayer Aktiengesellschaft (BAYRY) Shareholder/Analyst Call Transcript
Bayer Aktiengesellschaft (BAYRY) Shareholder/Analyst Call Transcript
Bayer shares slide after U.S. Supreme Court split over Bayer's fight against Roundup lawsuits
Shares in chemicals giant Bayer fell as much as 6.5% on Tuesday after the U.S. Supreme Court appeared split over what view it will form in Bayer's fight against Roundup lawsuits.
US Supreme Court hears Bayer's fight against Roundup lawsuits
The U.S. Supreme Court is set on Monday to consider Bayer AG's effort to shut down thousands of lawsuits accusing the company of failing to warn users that the active ingredient in its Roundup weedkiller causes cancer.
